2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting
Singh S, Hope T, Bergsland E, Bodei L, Bushnell D, Chan J, Chasen B, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman K, Halperin D, Lewis M, Lindwasser O, Myrehaug S, Raj N, Reidy-Lagunes D, Soares H, Strosberg J, Kohn E, Kunz P, Bergsland E, Beveridge T, Bodei L, Borek A, Brockman M, Bushnell D, Capala J, Chan J, Chasen B, Chauhan A, Das S, Dasari N, Davies-Venn C, Del Rivero J, Demaria S, Donoghue M, Eads J, El-Haddad G, Fielman N, Fishbein L, Gericke G, Goodman K, Halperin D, Hendifar A, Hicks R, Hobbs R, Hobday T, Hope T, Iyer R, Jaffe D, Kennedy A, Kohn E, Kulke M, Kunos C, Kunz P, Lewis M, Lin F, Lindwasser W, Mailman J, McDonald M, McEwan S, Myrehaug S, Nakasato A, Nothwehr S, Ou F, Padda S, Pavel M, Pilowa A, Raj N, Ramnaraign B, Reidy-Lagunes D, Rubinstein L, Saletan S, Shah M, Singh S, Soares H, Soulen M, Strosberg J, Untch B, Wahba M, Wong R, Yao J. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. Journal Of The National Cancer Institute 2023, 115: 1001-1010. PMID: 37255328, PMCID: PMC10483264, DOI: 10.1093/jnci/djad096.Peer-Reviewed Original ResearchConceptsPeptide receptor radionuclide therapyClinical trialsNeuroendocrine tumorsNeuroendocrine neoplasmsClinical trial recommendationsLiver-dominant diseaseReceptor radionuclide therapyTumor clinical trialsUse of dosimetryImmunotherapy combinationsTherapeutic optionsTreatment optionsGastroenteropancreatic NETsTrial recommendationsConsensus reportNew agentsInhibitor combinationsRadionuclide therapyPatient advocatesMultidisciplinary expertsOptimal sequencingTrialsTreatmentTherapyDisease
2021
Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors
Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice 2021, 18: 258-264. PMID: 34652954, DOI: 10.1200/op.21.00240.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsFunctional statusPrimary sitePrevalence of NETsMetastatic neuroendocrine tumorsExtent of diseaseOngoing clinical trialsSomatostatin receptor statusIndividualized treatment planHeterogeneous clinical entityPace of diseaseConsideration of patientsPerformance statusSystemic therapyReceptor statusTumor characteristicsClinical entityTherapeutic optionsPathologic classificationClinical trialsTherapeutic decisionsDiagnostic modalitiesTreatment planDiseasePatientsComparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.Peer-Reviewed Original ResearchConceptsNeuroendocrine neoplasmsClinical trialsNational Cancer Institute Clinical TrialsEU Clinical Trials RegisterCoprimary end pointsObjective response rateProgression-free survivalClinical Trials RegisterKi-67 indexAllied Health LiteratureQuality improvement studyPhase IISpecific disease populationsWeb of ScienceDrug licensureTrials RegisterCochrane DatabaseTumor differentiationNovel agentsDisease populationInclusion criteriaMAIN OUTCOMECumulative IndexEnrollment periodResponse rate
2020
A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS
Riess JW, Jahchan NS, Das M, Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment And Research Communications 2020, 23: 100174. PMID: 32413603, PMCID: PMC7572629, DOI: 10.1016/j.ctarc.2020.100174.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerMetastatic small cell lung cancerRadiographic progression-free survivalHigh-grade neuroendocrine carcinomaMedian overall survivalProgression-free survivalTricyclic antidepressantsClinical trialsLung cancerPrior chemotherapyFree survivalStable doseOverall survivalRadiographic benefitStudy entryNeuroendocrine carcinomaPreclinical modelsAntitumor effectsGrade 1Phase IIa clinical trialDose-escalation clinical trialHigh-grade neuroendocrine tumorsNeurocognitive adverse eventsEscalation clinical trial
2015
Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?
Narayanan S, Kunz P. Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors? International Journal Of Endocrine Oncology 2015, 2: 13-20. DOI: 10.2217/ije.14.37.Peer-Reviewed Original ResearchManagement of NETsNeuroendocrine tumorsCytotoxic chemotherapySystemic cytotoxic chemotherapyCurrent treatment guidelinesPresent clinical trialGroup of biologicallyBiologic therapyTreatment guidelinesClinical trialsHeterogeneous neoplasmsChemotherapyDegree of responsivenessTherapyTumorsNeoplasmsTrialsBiologics
2012
A renaissance in therapeutic options for pancreatic neuroendocrine tumors.
Kunz PL. A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society Of Clinical Oncology Educational Book 2012, 271-4. PMID: 24451747, DOI: 10.14694/edbook_am.2012.32.136.Peer-Reviewed Original ResearchProgression-free survivalPancreatic neuroendocrine tumorsNeuroendocrine tumorsTherapeutic optionsRandomized placebo-controlled studyPlacebo-controlled studyNovel therapeutic optionsChemotherapy backboneLocoregional diseaseAdvanced diseaseBiologic therapySurgical resectionSomatostatin analoguesClinical trialsDrug AdministrationU.S. FoodAntiproliferative agentsTumorsDiseaseFuture studiesResectionEverolimusSunitinibPatientsOptions
2011
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateConceptsIntensity-modulated radiotherapyLocal-regional control ratesPancreatic adenocarcinomaAdjuvant patientsDefinitive patientsControl rateSurvival rateGrade 3 late toxicityRecurrence-free survival ratesThree-dimensional conformal radiotherapyOverall survival rateProspective clinical trialsRecurrence-free survivalDurable disease controlPlanning target volumeGreater acute toxicityAcute toxicityLate toxicityOverall survivalSystemic therapyMedian agePancreatic cancerClinical trialsPrescription doseGrade 3